Genentech pays $725mm up front for early-stage cancer start-up Seragon
Roche’s Genentech Inc. shelled out $725mm in up-front cash to buy privately held Seragon Pharmaceuticals Inc., an early-stage oncology company that could also get up to $1bn in earn-outs.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com